pentoxifylline has been researched along with Gastrointestinal Hemorrhage in 7 studies
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both corticosteroid and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis." | 9.19 | Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. ( Baik, SK; Jang, JY; Kim, DJ; Kim, HS; Kim, IH; Kim, SG; Kim, TY; Kim, YS; Lee, HJ; Lee, JS; Park, SH; Park, SY; Sohn, JH; Suh, SJ; Suk, KT; Tak, WY; Um, SH; Yim, HJ; Yoon, KT, 2014) |
| "Both corticosteroid and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis." | 5.19 | Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. ( Baik, SK; Jang, JY; Kim, DJ; Kim, HS; Kim, IH; Kim, SG; Kim, TY; Kim, YS; Lee, HJ; Lee, JS; Park, SH; Park, SY; Sohn, JH; Suh, SJ; Suk, KT; Tak, WY; Um, SH; Yim, HJ; Yoon, KT, 2014) |
| "Treatment with pentoxifylline was the only factor associated with liver-related complications." | 2.75 | Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. ( Barraud, H; Carbonell, N; Condat, B; Lebrec, D; Moreau, R; Oberti, F; Perarnau, JM; Poynard, T; Ramond, MJ; Renard, P; Saliba, F; Thabut, D, 2010) |
| "Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis." | 1.62 | The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment. ( Chen, JY; Chen, YC; Fang, JH; Ho, CH; Hsing, CH; Liang, FW; Wu, CC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, JH | 1 |
| Chen, YC | 1 |
| Ho, CH | 1 |
| Chen, JY | 1 |
| Hsing, CH | 1 |
| Liang, FW | 1 |
| Wu, CC | 1 |
| Kulianda, OO | 1 |
| Park, SH | 1 |
| Kim, DJ | 1 |
| Kim, YS | 1 |
| Yim, HJ | 1 |
| Tak, WY | 1 |
| Lee, HJ | 1 |
| Sohn, JH | 1 |
| Yoon, KT | 1 |
| Kim, IH | 1 |
| Kim, HS | 1 |
| Um, SH | 1 |
| Baik, SK | 1 |
| Lee, JS | 1 |
| Suk, KT | 1 |
| Kim, SG | 1 |
| Suh, SJ | 1 |
| Park, SY | 1 |
| Kim, TY | 1 |
| Jang, JY | 1 |
| Lebrec, D | 1 |
| Thabut, D | 1 |
| Oberti, F | 1 |
| Perarnau, JM | 1 |
| Condat, B | 1 |
| Barraud, H | 1 |
| Saliba, F | 1 |
| Carbonell, N | 1 |
| Renard, P | 1 |
| Ramond, MJ | 1 |
| Moreau, R | 1 |
| Poynard, T | 1 |
| Venkitaraman, R | 1 |
| Price, A | 1 |
| Coffey, J | 1 |
| Norman, AR | 1 |
| James, FV | 1 |
| Huddart, RA | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Rees, CJ | 1 |
| Hudson, M | 1 |
| Record, CO | 1 |
| Oren, R | 1 |
| Yishar, U | 1 |
| Lysy, J | 1 |
| Livshitz, T | 1 |
| Ligumsky, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure[NCT00162552] | Phase 3 | 342 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
1 review available for pentoxifylline and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Therapeutic modalities in portal hypertension.
Topics: Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertension, Portal; Pentoxifylline; Portasystem | 1997 |
3 trials available for pentoxifylline and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial.
Topics: Adult; Anti-Inflammatory Agents; Drug Monitoring; Female; Gastrointestinal Hemorrhage; Hepatitis, Al | 2014 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial.
Topics: Gastrointestinal Hemorrhage; Humans; Pentoxifylline; Platelet Aggregation Inhibitors; Proctitis; Rad | 2008 |
3 other studies available for pentoxifylline and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment.
Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Intracrani | 2021 |
[Dynamics of the cytokines profile in pentoxiphylline application under conditions of polytrauma].
Topics: Animals; Animals, Outbred Strains; Femoral Fractures; Free Radical Scavengers; Gastrointestinal Hemo | 2013 |
Pentoxifylline-induced gastrointestinal bleeding.
Topics: Duodenal Ulcer; Gastrointestinal Hemorrhage; Humans; Pentoxifylline; Peptic Ulcer Hemorrhage | 1991 |